导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.78% | 798/4773 |
| 近一周 | -1.39% | 428/5462 |
| 近一月 | -1.70% | 1011/5421 |
| 近一季 | -7.54% | 2441/5209 |
| 近半年 | 1.17% | 1075/4920 |
| 近一年 | 14.34% | 732/4366 |
| 近两年 | 62.78% | 1128/2954 |
| 近三年 | 45.57% | 616/2253 |
| 成立以来 | 170.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.61% 879/4961 |
20.19% 1246/5312 |
- - |
- - |
| 2025 | 21.06% 2060/4813 |
-0.32% 2198/3635 |
2.29% 1674/4076 |
16.55% 2637/4524 |
1.87% 1181/4813 |
| 2024 | 19.16% 549/3463 |
3.58% 540/2808 |
0.03% 657/3014 |
16.28% 1490/3129 |
-1.09% 1586/3463 |
| 2023 | -10.32% 1287/2656 |
2.35% 1369/2280 |
-4.27% 1115/2385 |
-1.79% 581/2515 |
-6.80% 1926/2655 |
| 2022 | -19.90% 914/2207 |
-12.70% 649/1919 |
6.19% 755/2016 |
-13.68% 947/2113 |
0.10% 1543/2208 |
| 2021 | -1.08% 778/1822 |
-0.86% 400/1255 |
4.80% 845/1330 |
-5.26% 787/1466 |
0.50% 1100/1822 |
| 2020 | 48.50% 184/1250 |
-7.37% 539/1028 |
18.81% 323/1067 |
16.57% 148/1164 |
15.76% 192/1184 |
| 2019 | 44.20% 177/1092 |
26.39% 410/754 |
0.18% 191/804 |
4.52% 198/850 |
8.96% 268/918 |
| 2018 | -27.02% 412/834 |
- - |
- - |
- - |
-15.15% 600/691 |
| 2017 | 25.28% 116/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.27% 279/605 |
- - |
- - |
- - |
- - |
| 2015 | 4.48% 226/575 |
- - |
- - |
- - |
- - |
| 2014 | 48.37% 96/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.68% 118/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 浙商沪深300指数增强(LOF)A VS. 长安沪深300非周期A(740101) |